Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Xeloda To Be Reimbursed By Medicare As Prodrug Of 5-FU

Executive Summary

Roche's oral treatment for late-stage metastatic breast cancer Xeloda (capecitabine) will be covered for outpatient use by Medicare effective Jan. 1, 1999, the company announced Jan 13.
Advertisement

Related Content

Roche Xeloda Medicare Part B Reimbursement Raised To 90% Of AWP
Roche Xeloda Medicare Part B Reimbursement Raised To 90% Of AWP
Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Medicare Could Cover Melphalan Regimen For 1000 Stem Cell Procedures
Medicare Could Cover Melphalan Regimen For 1000 Stem Cell Procedures
Advertisement
UsernamePublicRestriction

Register

PS033493

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel